Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Structural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase

Open access

Abstract

Thalidomide and its derivatives, lenalidomide and pomalidomide, are immune modulatory drugs (IMiDs) used in the treatment of haematologic malignancies. IMiDs bind CRBN, the substrate receptor of the CUL4-RBX1-DDB1-CRBN (also known as CRL4(CRBN)) E3 ubiquitin ligase, and inhibit ubiquitination of endogenous CRL4(CRBN) substrates. Unexpectedly, IMiDs also repurpose the ligase to target new proteins for degradation. Lenalidomide induces degradation of the lymphoid transcription factors Ikaros and Aiolos (also known as IKZF1 and IKZF3), and casein kinase 1α (CK1α), which contributes to its clinical efficacy in the treatment of multiple myeloma and 5q-deletion associated myelodysplastic syndrome (del(5q) MDS), respectively. How lenalidomide alters the specificity of the ligase to degrade these proteins remains elusive. Here we present the 2.45 Å crystal structure of DDB1-CRBN bound to lenalidomide and CK1α. CRBN and lenalidomide jointly provide the binding interface for a CK1α β-hairpin-loop located in the kinase N-lobe. We show that CK1α binding to CRL4(CRBN) is strictly dependent on the presence of an IMiD. Binding of IKZF1 to CRBN similarly requires the compound and both, IKZF1 and CK1α, use a related binding mode. Our study provides a mechanistic explanation for the selective efficacy of lenalidomide in del(5q) MDS therapy. We anticipate that high-affinity protein-protein interactions induced by small molecules will provide opportunities for drug development, particularly for…

Overview

Integrity signals

Registry

Crossref · 10.1038/nature16979

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

27 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 41 references

Cited by

See all 620

Metadata

Authors
Petzold, G., Fischer, E. S., & Thomä, N. H.
Affiliations
University of Basel (CH)
Corresponding author
Thomä, Nicolas H.
Venue
Nature
Published
2016-02-24
Volume
532
Issue
7597
Pages
127-130
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W2283442479
Cited by
620
References
41
Citations by year
2026: 77 · 2025: 84 · 2024: 80 · 2023: 62 · 2022: 56 · 2021: 64 · 2020: 63 · 2019: 49 · 2018: 40 · 2017: 33 · 2016: 10
FWCI
23.05
Type
journal article
Language
en
Open access
Licence
  • other-oa
  • www.springer.com/tdm (tdm)
Locations
  • Nature (publishedVersion)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DORA PSI (Paul Scherrer Institute) (submittedVersion)
  • Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, other-oa)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
Keywords
lenalidomide, CK1α, Ikaros, IKZF1, IKZF3, cereblon, thalidomide derivatives, protein degradation, ubiquitination, protein-protein interaction, multiple myeloma, hematologic malignancies, protein structure, drug repurposing
MeSH terms
Lenalidomide, Binding Sites, Humans, Models, Molecular, Protein Binding, Structure-Activity Relationship, Substrate Specificity, Thalidomide, Crystallography, X-Ray, Catalytic Domain, Ubiquitin-Protein Ligases, Casein Kinase Ialpha, Ikaros Transcription Factor, Ubiquitination, Proteolysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Structural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase. https://app.cochat.ai/papers/10.1038/nature16979
The paper
Petzold, G., Fischer, E. S., & Thomä, N. H. (2016). Structural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase. Nature. https://doi.org/10.1038/nature16979

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.